Drug Trial Radar · NCT05284799
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
May 9, 2022
Primary completion
Jul 19, 2022
Study completion Dec 9, 2022
Sponsor
- Lead sponsor
- OsivaxIndustry
- Sponsor type
- Industry
- Collaborators
- Northern Beaches Clinical Research; Novotech (Australia) Pty Limited; Harmony Clinical Research BVBA
- First posted
- Mar 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The present study will evaluate the concomitant administration of a Quadrivalent Inactivated Influenza Vaccine with the highest dose level of OVX836 (480µg) tested in the clinic to date, for which the likelihood for interference with Quadrivalent Inactivated Influenza Vaccine is considered the highest.
Conditions
- Influenza
Interventions
OVX836 480µgBiological
One single administration intramuscularly at Day 1
Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)Biological
One single administration intramuscularly at Day 1
PlaceboBiological
One single administration intramuscularly at Day 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of seroconversion determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29 versus pre-injection baseline (Day 1)
- Proportion of subjects achieving a titer ≥1:40 at Day 29 determined using Hemagglutination-Inhibition assay, for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29
- Number of Hemagglutination-Inhibition assay titers geometric mean ratios >2.5 for the four influenza strains contained in the Quadrivalent Influenza Vaccine.Time frame: At Day 29 versus pre-injection baseline (Day 1)
- Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic signs and symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: During 7 days after vaccine administration
- Proportion of subjects reporting unsolicited AEsTime frame: During 29 days after vaccine administration
- Proportion of subjects with Influenza-Like-Illness casesTime frame: During the whole study duration, 180 days
- Severity scores of Influenza-Like-Illness cases (as per Flu-PRO questionnaire)Time frame: During the whole study duration, 180 days
- Proportion of subjects reporting Serious Adverse EventsTime frame: During the whole study duration, 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northern Beaches Clinical Research
Brookvale, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.